Treatment of age-related macular degeneration

被引：3
|
作者：
Bunting, Roland [1 ]
Guymer, Robyn [1 ]
机构：
[1] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia
来源：
AUSTRALIAN PRESCRIBER | 2012年 / 35卷 / 03期
关键词：
anti-vascular endothelial growth factor; bevacizumab; choroidal neovascularisation; ranibizumab; RANIBIZUMAB; METAANALYSIS;
D O I：
10.18773/austprescr.2012.038
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Age-related macular degeneration is a common cause of visual loss. There may be choroidal neovascularisation or geographic atrophy. Evidence is accumulating for the importance of avoidable risk factors in age-related macular degeneration, such as smoking and obesity. Research confirms that there is an important hereditary component to the disease. Anti-vascular endothelial growth factors have improved the outlook for patients suffering from neovascular age-related macular degeneration. Recent work has concentrated on refining the frequency and pattern of delivery of these drugs to the vitreous cavity. There are few treatment options for geographic atrophy.
引用
收藏
页码：90 / 93
页数：4
相关论文
共 50 条
  • [31] VERTEPORFIN COMBINATION REGIMENS IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Shah, Gaurav K.
    Sang, Delia N.
    Hughes, Mark S.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (02): : 133 - 148
  • [32] Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration
    Novack, Gary D.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2008, 48 : 61 - 78
  • [33] Ranibizumab in neovascular age-related macular degeneration
    Eng, Kenneth T.
    Kertes, Peter J.
    CLINICAL INTERVENTIONS IN AGING, 2006, 1 (04) : 451 - 466
  • [34] Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration
    Abouammoh, Marwan
    Sharma, Sanjay
    CURRENT OPINION IN OPHTHALMOLOGY, 2011, 22 (03) : 152 - 158
  • [35] Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration
    Gamulescu M.-A.
    Radeck V.
    Lustinger B.
    Bianca Fink B.
    Helbig H.
    International Ophthalmology, 2010, 30 (3) : 261 - 266
  • [36] Pharmacogenetics of the Treatment Response of Age-Related Macular Degeneration with Ranibizumab and Bevacizumab
    Kanoff, Justin
    Miller, Joan
    SEMINARS IN OPHTHALMOLOGY, 2013, 28 (5-6) : 355 - 360
  • [37] A new era in the treatment of age-related macular degeneration: from Factor X to antiangiogenesis
    Gamulescu, Maria-Andreea
    Helbig, Horst
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (11) : 1351 - 1363
  • [38] Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration
    Real, Juan P.
    Luna, Jose D.
    Urrets-Zavalia, Julio A.
    De Santis, Mariana O.
    Palma, Santiago D.
    Granero, Gladys E.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2013, 23 (06) : 857 - 864
  • [39] Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept
    Hara, Chikako
    Wakabayashi, Taku
    Fukushima, Yoko
    Sayanagi, Kaori
    Kawasaki, Ryo
    Sato, Shigeru
    Sakaguchi, Hirokazu
    Nishida, Kohji
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 257 (11) : 2559 - 2569
  • [40] Cystoid Macular Degeneration in Exudative Age-Related Macular Degeneration
    Querques, Giuseppe
    Coscas, Florence
    Forte, Raimondo
    Massamba, Nathalie
    Sterkers, Margaret
    Souied, Eric H.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2011, 152 (01) : 100 - 107
12345